AL淀粉样变性患者的真实世界治疗模式、费用和结果：Optum EHR和商业索赔数据库分析

数据集获取（Figshare）

• 源站标题：Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases
• DOI：10.6084/m9.figshare.21394688.v1
• 发布日期：2022-10-25
• 文件数：2 个
• 文件总体积：633.51 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Real-world_treatment_patterns_costs_and_outcomes_in_patients_with_AL_amyloidosis_analysis_of_the_Optum_EHR_and_commercial_claims_databases/21394688

命令行下载

curl -L -o "iamy_a_2137400_sm3084.jpg" "https://ndownloader.figshare.com/files/37983191"
curl -L -o "iamy_a_2137400_sm2848.docx" "https://ndownloader.figshare.com/files/37983194"

文件清单

• iamy_a_2137400_sm3084.jpg（480.85 KB）
• iamy_a_2137400_sm2848.docx（152.66 KB）

文件总体积 633.51 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This study characterised real-world treatment patterns, clinical outcomes, and cost-of-illness in patients with light-chain (AL) amyloidosis.
Data were extracted from the US-based Optum® EHR and Clinformatics® Data Mart (claims) databases (2008–2019) for patients newly diagnosed with AL amyloidosis and who initiated anti-plasma cell therapies. Healthcare resource utilisation (HCRU) and related costs were compared across lines of therapy (LOT). Incidences of cardiac and renal failure were evaluated using the Kaplan-Meier method.
About 1347 patients (EHR, n = 776; claims, n = 571) were included. Median age was 68 years; 56.8% were male. At initial diagnosis, 33.1% and 15.1% of patients had cardiac and renal failure, respectively. Most patients received bortezomib-containing treatment in LOT1 (69%); bortezomib-cyclophosphamide-dexamethasone was most common (26%). HCRU was similar across LOTs. Mean per-patient-per-month and per-patient-per-LOT costs were $19,343 and $105,944 for LOT1, $19,183 and $95,793 for LOT2, and $16,611 and $128,446 for LOT3, respectively. Costs were primarily driven by anti-plasma cell therapies, outpatient visits, and hospitalisations. The 5-year cardiac and renal failure rates following initial diagnosis were 64.5% and 39.0%, respectively.
AL amyloidosis is associated with substantial costs and suboptimal outcomes, highlighting the need for new therapeutic approaches to prevent organ deterioration, and reduce disease burden.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.21394688.v1（source: https://tandf.figshare.com/articles/dataset/Real-world_treatment_patterns_costs_and_outcomes_in_patients_with_AL_amyloidosis_analysis_of_the_Optum_EHR_and_commercial_claims_databases/21394688）。